Average Approval Time Is Slower For Drugs, Faster For Biologics
This article was originally published in Pharmaceutical Approvals Monthly
Average time to approval rose in 2004 to 18.7 months for NMEs, but biologics average was significantly lower at 20.2 months. 2003 averages were 17.1 for drugs, 36.9 for biologics
You may also be interested in...
FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.
FDA approved approximately one-third of new molecular entities with user fee deadlines in 2002 on the first cycle.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011